---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023095"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2026-05-14T20:15:44+00:00"
generated_at: "2026-05-14T20:51:33.443077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance

## Summary
- Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.
- Adjusted EBITDA $1.6M (17% margin) vs $0.8M Pro Forma in prior year; operating income margin improved to 12% from 6% Pro Forma.
- Thyroid test volume increased 10% YoY; revenue per test up 3%; active accounts increased 5%.
- Gross margin expanded to 65% from 59% Pro Forma; company debt-free with $8.7M cash collections in Q1.
- Reaffirmed 2026 guidance of ~16% year-over-year thyroid revenue growth.

## SEC filing metadata
- accession: 0001493152-26-023095
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2026-05-14T20:15:44+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/0001493152-26-023095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023095
- JSON: https://secwatch.observer/filing/0001493152-26-023095.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023095.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2026 results: revenue $9.0 million, net income $0.8 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: $9.0 million
  - Net income: $0.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/0001493152-26-023095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.